F-group (family)
10.3.1.1 TNF
Ligands and drugs
658
Member domains
307
with ligand contacts (≤ 4 Å)
46.7% of members
286
with DrugDomain annotations
43.5% of members
80
with a DrugBank compound
12.2% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 10.3.1.1 belongs to X-group 10 jelly-roll, which binds 8.5 ligand superclasses per 20 proteins, broader than 66% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 19 |
| DB03570 | 144 | Tris-Hydroxymethyl-Methyl-Ammonium | 2 |
| DB04332 | ETE | 2-{2-[2-2-(Methoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethanol | 2 |
| DB00480 | — | — | 1 |
| DB00608 | — | Chloroquine | 1 |
| DB00668 | — | Epinephrine | 1 |
| DB00852 | — | — | 1 |
| DB01407 | — | — | 1 |
| DB01411 | — | Pranlukast | 1 |
| DB01427 | — | — | 1 |
| DB04297 | — | Trichostatin A | 1 |
| DB05412 | — | Talmapimod | 1 |
| DB05470 | — | — | 1 |
| DB05513 | — | — | 1 |
| DB05767 | — | — | 1 |
| DB05869 | — | Ethyl pyruvate | 1 |
| DB05968 | — | — | 1 |
| DB05992 | — | Plinabulin | 1 |
| DB06444 | — | — | 1 |
| DB08217 | MTN | S-[(1-Hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl] methanesulfonothioate | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 74 |
| JNI | ~{N}4-(phenylmethyl)-~{N}4-[2-[3-(2-piperazin-1-ylpyrimidin-5-yl)phenyl]phenyl]pyrimidine-2,4-diamine | 47 |
| CL | CHLORIDE ION | 29 |
| ZNmetal | ZINC ION | 18 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 16 |
| NImetal | NICKEL (II) ION | 7 |
| A1CBZ | (6R,13R,14S)-1-(difluoromethoxy)-11-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-7H-6,14-methanopyrido[3',2':4,5]imidazo[1,2-b][2,5]benzodiazocin-5(14H)-one | 6 |
| A1CCE | (4S,8aR)-7-{5-[(6R,13R,14S)-5,14-dihydro-7H-6,14-methanopyrido[3',2':4,5]imidazo[1,2-b][2,5]benzodiazocin-11-yl]pyrimidin-2-yl}hexahydroimidazo[1,5-a]pyrazin-3(2H)-one | 6 |
| A7G | 1-{[2-(difluoromethoxy)phenyl]methyl}-2-methyl-6-[6-(piperazin-1-yl)pyridin-3-yl]-1H-benzimidazole | 6 |
| D84 | 5-(1-{[2-(difluoromethoxy)phenyl]methyl}-2-{[3-(2-oxopyrrolidin-1-yl)phenoxy]methyl}-1H-benzimidazol-6-yl)pyridin-2(1H)-one | 6 |
| UTJ | [4-(isoquinolin-8-yl)phenyl]acetonitrile | 6 |
| UTM | 8-[4-(2-{5-[(4-methylpiperazin-1-yl)methyl]-2-(1H-pyrrolo[3,2-c]pyridin-3-yl)phenoxy}ethyl)phenyl]isoquinoline | 6 |
| UTS | 1-benzyl-1H-benzimidazole | 6 |
| UTY | 3-[(6-{2-[(3R)-4-(hydroxyacetyl)-3-methylpiperazin-1-yl]pyrimidin-5-yl}-2,2-dimethyl-3-oxo-2,3-dihydro-1H-indol-1-yl)methyl]pyridine-2-carbonitrile | 6 |
| 307 | 6,7-DIMETHYL-3-[(METHYL{2-[METHYL({1-[3-(TRIFLUOROMETHYL)PHENYL]-1H-INDOL-3-YL}METHYL)AMINO]ETHYL}AMINO)METHYL]-4H-CHROMEN-4-ONE | 4 |
| NAmetal | SODIUM ION | 4 |
| A1CB0 | (6R,13R,14R)-10-fluoro-11-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-7H-6,14-methanopyrido[3',2':4,5]imidazo[1,2-b][2,5]benzodiazocin-5(14H)-one | 3 |
| A1CB1 | 2-{5-[(1S,10S)-1-phenyl-1,2,3,4-tetrahydropyrido[1,2-a][1,3]benzimidazol-8-yl]pyrimidin-2-yl}propan-2-ol | 3 |
| A6Y | (S)-{1-[(2,5-dimethylphenyl)methyl]-1H-benzimidazol-2-yl}(pyridin-4-yl)methanol | 3 |
| A7A | (R)-{1-[(2,5-dimethylphenyl)methyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-benzimidazol-2-yl}(pyridin-4-yl)methanol | 3 |